Haleon not a party to U.S. litigation focused on Zantac - spokesperson

[August 11, 2022]   LONDON (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday.

The company logo for Haleon and the trading info is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., July 20, 2022. REUTERS/Brendan McDermid

"We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare," the spokesperson said in response to queries about sharp declines in Haleon shares.

Given over-the-counter Zantac has been sold by several companies over time, that "may make third parties liable ahead of any Haleon exposure," the spokesperson added.

(Reporting by Natalie Grover in London)

[© 2022 Thomson Reuters. All rights reserved.]
This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.